133 related articles for article (PubMed ID: 10147053)
1. The economic impact of HA-1A (Centoxin) against endotoxin.
Barriere SL
Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
Chalfin DB; Holbein ME; Fein AM; Carlon GC
JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HA-1A treatment for patients with sepsis.
van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
[TBL] [Abstract][Full Text] [Related]
5. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
Luce JM
Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
[TBL] [Abstract][Full Text] [Related]
7. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
8. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis.
Chalfin DB; Fein AM
Clin Infect Dis; 1993 Nov; 17 Suppl 2():S520-4. PubMed ID: 8274619
[TBL] [Abstract][Full Text] [Related]
9. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
Linden PK; Angus DC; Chelluri L; Branch RA
J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
[TBL] [Abstract][Full Text] [Related]
10. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
Schulman KA; Glick HA; Rubin H; Eisenberg JM
JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
[TBL] [Abstract][Full Text] [Related]
12. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
13. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
[No Abstract] [Full Text] [Related]
14. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
Derkx B; Wittes J; McCloskey R
Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to endotoxin in the management of sepsis.
Fang KC
West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
[TBL] [Abstract][Full Text] [Related]
17. [Septomonab (Centoxin) in the treatment of gram-negative septicemia].
Fomsgaard A
Ugeskr Laeger; 1993 Apr; 155(14):1066-71. PubMed ID: 8497944
[No Abstract] [Full Text] [Related]
18. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
Badía X; Segú L; García Alonso F; Rovira J
Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
Van Hout BA; Rutten FF; Lorijn RH
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
